Pharmosa Biopharm Inc.

Pharmosa Biopharm Inc. is a biotechnology company specializing in the research, development, and commercialization of novel pharmaceuticals, with a strong emphasis on innovative drug delivery systems. Founded in 2000 and headquartered in Taipei City, Taiwan, the company leverages proprietary formulation and manufacturing technologies to advance treatments for complex medical conditions. One of its leading developments includes L606, an inhalation and device combination therapy aimed at treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, as well as L608, which targets pulmonary vascular disease. Pharmosa Biopharm Inc. collaborates with global partners and pursues regulatory approvals through strategic pathways such as 505(b)(2) or hybrid applications, enhancing its ability to bring therapies efficiently to market. Positioned within the healthcare sector and the broader biotechnology industry, the organization contributes to medical innovation and the advancement of specialized respiratory therapies, reflecting its commitment to addressing unmet clinical needs.